Segment (Tables)

3 Months Ended

Mar. 31, 2026

Segment Reporting [Abstract]

Schedule of Significant Expense Categories Within Net Loss Presented on the Statement of Operations

The significant expense categories within net loss are presented on the statements of operations. The research and development expenses have been disaggregated as follows (in thousands):


		Three Months Ended March 31,
		2026				2025
Research and engineering expenses		$	29,483			$	33,627
Clinical expenses			35,564				22,960
In-process research and development expenses			5,000				—
Total research and development expenses			70,047				56,587
General and administrative expenses			17,290				14,796
Other segment items#			(4,379	)			(3,140	)
Net loss		$	82,958			$	68,243

# Other segment items is comprised of interest income (expense), net and other income (expense), net.